nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—Melatonin—MT3—urinary bladder cancer	0.0252	0.688	CrCbGaD
Rizatriptan—Melatonin—MPO—urinary bladder cancer	0.00654	0.178	CrCbGaD
Rizatriptan—Melatonin—ESR1—urinary bladder cancer	0.0049	0.134	CrCbGaD
Rizatriptan—Pain—Cisplatin—urinary bladder cancer	0.00107	0.00112	CcSEcCtD
Rizatriptan—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00107	0.00111	CcSEcCtD
Rizatriptan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00107	0.00111	CcSEcCtD
Rizatriptan—Dysuria—Epirubicin—urinary bladder cancer	0.00106	0.0011	CcSEcCtD
Rizatriptan—Dizziness—Thiotepa—urinary bladder cancer	0.00106	0.0011	CcSEcCtD
Rizatriptan—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00106	0.0011	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00105	0.0011	CcSEcCtD
Rizatriptan—Urticaria—Fluorouracil—urinary bladder cancer	0.00105	0.00109	CcSEcCtD
Rizatriptan—Dysphagia—Doxorubicin—urinary bladder cancer	0.00105	0.00109	CcSEcCtD
Rizatriptan—Pollakiuria—Epirubicin—urinary bladder cancer	0.00105	0.00109	CcSEcCtD
Rizatriptan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00105	0.00109	CcSEcCtD
Rizatriptan—Sweating—Methotrexate—urinary bladder cancer	0.00104	0.00108	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00104	0.00108	CcSEcCtD
Rizatriptan—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00103	0.00108	CcSEcCtD
Rizatriptan—Paraesthesia—Etoposide—urinary bladder cancer	0.00103	0.00107	CcSEcCtD
Rizatriptan—Dyspnoea—Etoposide—urinary bladder cancer	0.00103	0.00107	CcSEcCtD
Rizatriptan—Somnolence—Etoposide—urinary bladder cancer	0.00102	0.00106	CcSEcCtD
Rizatriptan—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00102	0.00106	CcSEcCtD
Rizatriptan—Epistaxis—Methotrexate—urinary bladder cancer	0.00102	0.00106	CcSEcCtD
Rizatriptan—Vomiting—Thiotepa—urinary bladder cancer	0.00102	0.00106	CcSEcCtD
Rizatriptan—Rash—Thiotepa—urinary bladder cancer	0.00101	0.00105	CcSEcCtD
Rizatriptan—Dermatitis—Thiotepa—urinary bladder cancer	0.00101	0.00105	CcSEcCtD
Rizatriptan—Headache—Thiotepa—urinary bladder cancer	0.001	0.00104	CcSEcCtD
Rizatriptan—Decreased appetite—Etoposide—urinary bladder cancer	0.001	0.00104	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000993	0.00103	CcSEcCtD
Rizatriptan—Body temperature increased—Cisplatin—urinary bladder cancer	0.000993	0.00103	CcSEcCtD
Rizatriptan—Fatigue—Etoposide—urinary bladder cancer	0.000992	0.00103	CcSEcCtD
Rizatriptan—Constipation—Etoposide—urinary bladder cancer	0.000984	0.00102	CcSEcCtD
Rizatriptan—Pain—Etoposide—urinary bladder cancer	0.000984	0.00102	CcSEcCtD
Rizatriptan—Dysuria—Doxorubicin—urinary bladder cancer	0.000981	0.00102	CcSEcCtD
Rizatriptan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000976	0.00101	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000975	0.00101	CcSEcCtD
Rizatriptan—Sweating—Epirubicin—urinary bladder cancer	0.000969	0.00101	CcSEcCtD
Rizatriptan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000969	0.00101	CcSEcCtD
Rizatriptan—Asthenia—Gemcitabine—urinary bladder cancer	0.000967	0.001	CcSEcCtD
Rizatriptan—Pharyngitis—Methotrexate—urinary bladder cancer	0.000963	0.001	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000958	0.000995	CcSEcCtD
Rizatriptan—Epistaxis—Epirubicin—urinary bladder cancer	0.000954	0.000991	CcSEcCtD
Rizatriptan—Pruritus—Gemcitabine—urinary bladder cancer	0.000953	0.00099	CcSEcCtD
Rizatriptan—Nausea—Thiotepa—urinary bladder cancer	0.000951	0.000988	CcSEcCtD
Rizatriptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000948	0.000985	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000941	0.000978	CcSEcCtD
Rizatriptan—Pruritus—Fluorouracil—urinary bladder cancer	0.000937	0.000974	CcSEcCtD
Rizatriptan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000925	0.000961	CcSEcCtD
Rizatriptan—Bradycardia—Epirubicin—urinary bladder cancer	0.000924	0.00096	CcSEcCtD
Rizatriptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000922	0.000958	CcSEcCtD
Rizatriptan—Urticaria—Etoposide—urinary bladder cancer	0.000914	0.00095	CcSEcCtD
Rizatriptan—Abdominal pain—Etoposide—urinary bladder cancer	0.000909	0.000945	CcSEcCtD
Rizatriptan—Body temperature increased—Etoposide—urinary bladder cancer	0.000909	0.000945	CcSEcCtD
Rizatriptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000906	0.000942	CcSEcCtD
Rizatriptan—Tinnitus—Methotrexate—urinary bladder cancer	0.000904	0.00094	CcSEcCtD
Rizatriptan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000903	0.000938	CcSEcCtD
Rizatriptan—Asthenia—Cisplatin—urinary bladder cancer	0.000901	0.000936	CcSEcCtD
Rizatriptan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000901	0.000936	CcSEcCtD
Rizatriptan—Sweating—Doxorubicin—urinary bladder cancer	0.000897	0.000932	CcSEcCtD
Rizatriptan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000882	0.000917	CcSEcCtD
Rizatriptan—Angiopathy—Methotrexate—urinary bladder cancer	0.00088	0.000914	CcSEcCtD
Rizatriptan—Dizziness—Fluorouracil—urinary bladder cancer	0.000876	0.00091	CcSEcCtD
Rizatriptan—Chills—Methotrexate—urinary bladder cancer	0.00087	0.000904	CcSEcCtD
Rizatriptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000859	0.000893	CcSEcCtD
Rizatriptan—Vomiting—Gemcitabine—urinary bladder cancer	0.000857	0.00089	CcSEcCtD
Rizatriptan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000855	0.000888	CcSEcCtD
Rizatriptan—Mental disorder—Methotrexate—urinary bladder cancer	0.00085	0.000883	CcSEcCtD
Rizatriptan—Rash—Gemcitabine—urinary bladder cancer	0.000849	0.000883	CcSEcCtD
Rizatriptan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000849	0.000882	CcSEcCtD
Rizatriptan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000848	0.000881	CcSEcCtD
Rizatriptan—Tinnitus—Epirubicin—urinary bladder cancer	0.000846	0.000879	CcSEcCtD
Rizatriptan—Erythema—Methotrexate—urinary bladder cancer	0.000844	0.000877	CcSEcCtD
Rizatriptan—Headache—Gemcitabine—urinary bladder cancer	0.000844	0.000877	CcSEcCtD
Rizatriptan—Flushing—Epirubicin—urinary bladder cancer	0.000842	0.000875	CcSEcCtD
Rizatriptan—Vomiting—Fluorouracil—urinary bladder cancer	0.000842	0.000875	CcSEcCtD
Rizatriptan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000836	0.000868	CcSEcCtD
Rizatriptan—Rash—Fluorouracil—urinary bladder cancer	0.000835	0.000868	CcSEcCtD
Rizatriptan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000834	0.000867	CcSEcCtD
Rizatriptan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000834	0.000866	CcSEcCtD
Rizatriptan—Headache—Fluorouracil—urinary bladder cancer	0.00083	0.000862	CcSEcCtD
Rizatriptan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000827	0.000859	CcSEcCtD
Rizatriptan—Asthenia—Etoposide—urinary bladder cancer	0.000825	0.000858	CcSEcCtD
Rizatriptan—Angiopathy—Epirubicin—urinary bladder cancer	0.000824	0.000856	CcSEcCtD
Rizatriptan—Chills—Epirubicin—urinary bladder cancer	0.000814	0.000846	CcSEcCtD
Rizatriptan—Pruritus—Etoposide—urinary bladder cancer	0.000814	0.000846	CcSEcCtD
Rizatriptan—Arrhythmia—Epirubicin—urinary bladder cancer	0.000811	0.000843	CcSEcCtD
Rizatriptan—Nausea—Gemcitabine—urinary bladder cancer	0.0008	0.000832	CcSEcCtD
Rizatriptan—Vomiting—Cisplatin—urinary bladder cancer	0.000798	0.00083	CcSEcCtD
Rizatriptan—Vision blurred—Methotrexate—urinary bladder cancer	0.000796	0.000827	CcSEcCtD
Rizatriptan—Mental disorder—Epirubicin—urinary bladder cancer	0.000795	0.000826	CcSEcCtD
Rizatriptan—Rash—Cisplatin—urinary bladder cancer	0.000792	0.000823	CcSEcCtD
Rizatriptan—Dermatitis—Cisplatin—urinary bladder cancer	0.000791	0.000822	CcSEcCtD
Rizatriptan—Erythema—Epirubicin—urinary bladder cancer	0.00079	0.000821	CcSEcCtD
Rizatriptan—Diarrhoea—Etoposide—urinary bladder cancer	0.000787	0.000818	CcSEcCtD
Rizatriptan—Nausea—Fluorouracil—urinary bladder cancer	0.000787	0.000818	CcSEcCtD
Rizatriptan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000783	0.000814	CcSEcCtD
Rizatriptan—Flushing—Doxorubicin—urinary bladder cancer	0.000779	0.00081	CcSEcCtD
Rizatriptan—Flatulence—Epirubicin—urinary bladder cancer	0.000779	0.000809	CcSEcCtD
Rizatriptan—Tension—Epirubicin—urinary bladder cancer	0.000775	0.000806	CcSEcCtD
Rizatriptan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000774	0.000804	CcSEcCtD
Rizatriptan—Nervousness—Epirubicin—urinary bladder cancer	0.000767	0.000797	CcSEcCtD
Rizatriptan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000762	0.000792	CcSEcCtD
Rizatriptan—Dizziness—Etoposide—urinary bladder cancer	0.000761	0.00079	CcSEcCtD
Rizatriptan—Muscle spasms—Epirubicin—urinary bladder cancer	0.00076	0.000789	CcSEcCtD
Rizatriptan—Vertigo—Methotrexate—urinary bladder cancer	0.000759	0.000788	CcSEcCtD
Rizatriptan—Chills—Doxorubicin—urinary bladder cancer	0.000754	0.000783	CcSEcCtD
Rizatriptan—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00075	0.00078	CcSEcCtD
Rizatriptan—Nausea—Cisplatin—urinary bladder cancer	0.000746	0.000775	CcSEcCtD
Rizatriptan—Vision blurred—Epirubicin—urinary bladder cancer	0.000745	0.000774	CcSEcCtD
Rizatriptan—Cough—Methotrexate—urinary bladder cancer	0.000737	0.000766	CcSEcCtD
Rizatriptan—Mental disorder—Doxorubicin—urinary bladder cancer	0.000736	0.000765	CcSEcCtD
Rizatriptan—Convulsion—Methotrexate—urinary bladder cancer	0.000732	0.00076	CcSEcCtD
Rizatriptan—Vomiting—Etoposide—urinary bladder cancer	0.000731	0.00076	CcSEcCtD
Rizatriptan—Erythema—Doxorubicin—urinary bladder cancer	0.000731	0.00076	CcSEcCtD
Rizatriptan—Agitation—Epirubicin—urinary bladder cancer	0.000726	0.000755	CcSEcCtD
Rizatriptan—Rash—Etoposide—urinary bladder cancer	0.000725	0.000754	CcSEcCtD
Rizatriptan—Dermatitis—Etoposide—urinary bladder cancer	0.000725	0.000753	CcSEcCtD
Rizatriptan—Headache—Etoposide—urinary bladder cancer	0.000721	0.000749	CcSEcCtD
Rizatriptan—Flatulence—Doxorubicin—urinary bladder cancer	0.00072	0.000749	CcSEcCtD
Rizatriptan—Arthralgia—Methotrexate—urinary bladder cancer	0.000719	0.000747	CcSEcCtD
Rizatriptan—Myalgia—Methotrexate—urinary bladder cancer	0.000719	0.000747	CcSEcCtD
Rizatriptan—Chest pain—Methotrexate—urinary bladder cancer	0.000719	0.000747	CcSEcCtD
Rizatriptan—Tension—Doxorubicin—urinary bladder cancer	0.000717	0.000745	CcSEcCtD
Rizatriptan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000716	0.000744	CcSEcCtD
Rizatriptan—Discomfort—Methotrexate—urinary bladder cancer	0.00071	0.000738	CcSEcCtD
Rizatriptan—Nervousness—Doxorubicin—urinary bladder cancer	0.00071	0.000738	CcSEcCtD
Rizatriptan—Vertigo—Epirubicin—urinary bladder cancer	0.00071	0.000738	CcSEcCtD
Rizatriptan—Syncope—Epirubicin—urinary bladder cancer	0.000709	0.000736	CcSEcCtD
Rizatriptan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000703	0.00073	CcSEcCtD
Rizatriptan—Palpitations—Epirubicin—urinary bladder cancer	0.000698	0.000726	CcSEcCtD
Rizatriptan—Confusional state—Methotrexate—urinary bladder cancer	0.000695	0.000722	CcSEcCtD
Rizatriptan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000694	0.000722	CcSEcCtD
Rizatriptan—Cough—Epirubicin—urinary bladder cancer	0.00069	0.000716	CcSEcCtD
Rizatriptan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000689	0.000716	CcSEcCtD
Rizatriptan—Vision blurred—Doxorubicin—urinary bladder cancer	0.000689	0.000716	CcSEcCtD
Rizatriptan—Convulsion—Epirubicin—urinary bladder cancer	0.000685	0.000711	CcSEcCtD
Rizatriptan—Nausea—Etoposide—urinary bladder cancer	0.000683	0.00071	CcSEcCtD
Rizatriptan—Hypertension—Epirubicin—urinary bladder cancer	0.000682	0.000709	CcSEcCtD
Rizatriptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000676	0.000702	CcSEcCtD
Rizatriptan—Chest pain—Epirubicin—urinary bladder cancer	0.000673	0.000699	CcSEcCtD
Rizatriptan—Myalgia—Epirubicin—urinary bladder cancer	0.000673	0.000699	CcSEcCtD
Rizatriptan—Arthralgia—Epirubicin—urinary bladder cancer	0.000673	0.000699	CcSEcCtD
Rizatriptan—Agitation—Doxorubicin—urinary bladder cancer	0.000672	0.000698	CcSEcCtD
Rizatriptan—Anxiety—Epirubicin—urinary bladder cancer	0.00067	0.000697	CcSEcCtD
Rizatriptan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000666	0.000692	CcSEcCtD
Rizatriptan—Discomfort—Epirubicin—urinary bladder cancer	0.000665	0.000691	CcSEcCtD
Rizatriptan—Dry mouth—Epirubicin—urinary bladder cancer	0.000658	0.000684	CcSEcCtD
Rizatriptan—Vertigo—Doxorubicin—urinary bladder cancer	0.000657	0.000683	CcSEcCtD
Rizatriptan—Anorexia—Methotrexate—urinary bladder cancer	0.000657	0.000683	CcSEcCtD
Rizatriptan—Syncope—Doxorubicin—urinary bladder cancer	0.000656	0.000681	CcSEcCtD
Rizatriptan—Confusional state—Epirubicin—urinary bladder cancer	0.00065	0.000676	CcSEcCtD
Rizatriptan—Palpitations—Doxorubicin—urinary bladder cancer	0.000646	0.000671	CcSEcCtD
Rizatriptan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000645	0.00067	CcSEcCtD
Rizatriptan—Oedema—Epirubicin—urinary bladder cancer	0.000645	0.00067	CcSEcCtD
Rizatriptan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000643	0.000668	CcSEcCtD
Rizatriptan—Cough—Doxorubicin—urinary bladder cancer	0.000638	0.000663	CcSEcCtD
Rizatriptan—Shock—Epirubicin—urinary bladder cancer	0.000634	0.000659	CcSEcCtD
Rizatriptan—Convulsion—Doxorubicin—urinary bladder cancer	0.000633	0.000658	CcSEcCtD
Rizatriptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000632	0.000657	CcSEcCtD
Rizatriptan—Hypertension—Doxorubicin—urinary bladder cancer	0.000631	0.000656	CcSEcCtD
Rizatriptan—Tachycardia—Epirubicin—urinary bladder cancer	0.000629	0.000654	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000628	0.000652	CcSEcCtD
Rizatriptan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000623	0.000648	CcSEcCtD
Rizatriptan—Insomnia—Methotrexate—urinary bladder cancer	0.000623	0.000648	CcSEcCtD
Rizatriptan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000622	0.000647	CcSEcCtD
Rizatriptan—Chest pain—Doxorubicin—urinary bladder cancer	0.000622	0.000647	CcSEcCtD
Rizatriptan—Myalgia—Doxorubicin—urinary bladder cancer	0.000622	0.000647	CcSEcCtD
Rizatriptan—Anxiety—Doxorubicin—urinary bladder cancer	0.00062	0.000645	CcSEcCtD
Rizatriptan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000619	0.000643	CcSEcCtD
Rizatriptan—Discomfort—Doxorubicin—urinary bladder cancer	0.000615	0.000639	CcSEcCtD
Rizatriptan—Anorexia—Epirubicin—urinary bladder cancer	0.000615	0.000639	CcSEcCtD
Rizatriptan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000614	0.000638	CcSEcCtD
Rizatriptan—Somnolence—Methotrexate—urinary bladder cancer	0.000613	0.000637	CcSEcCtD
Rizatriptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000609	0.000633	CcSEcCtD
Rizatriptan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000607	0.00063	CcSEcCtD
Rizatriptan—Confusional state—Doxorubicin—urinary bladder cancer	0.000602	0.000625	CcSEcCtD
Rizatriptan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000599	0.000622	CcSEcCtD
Rizatriptan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000597	0.00062	CcSEcCtD
Rizatriptan—Oedema—Doxorubicin—urinary bladder cancer	0.000597	0.00062	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000595	0.000618	CcSEcCtD
Rizatriptan—Fatigue—Methotrexate—urinary bladder cancer	0.000594	0.000617	CcSEcCtD
Rizatriptan—Pain—Methotrexate—urinary bladder cancer	0.000589	0.000612	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000588	0.00061	CcSEcCtD
Rizatriptan—Shock—Doxorubicin—urinary bladder cancer	0.000587	0.00061	CcSEcCtD
Rizatriptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000585	0.000608	CcSEcCtD
Rizatriptan—Insomnia—Epirubicin—urinary bladder cancer	0.000583	0.000606	CcSEcCtD
Rizatriptan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000582	0.000605	CcSEcCtD
Rizatriptan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000579	0.000602	CcSEcCtD
Rizatriptan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000577	0.000599	CcSEcCtD
Rizatriptan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000575	0.000597	CcSEcCtD
Rizatriptan—Somnolence—Epirubicin—urinary bladder cancer	0.000573	0.000596	CcSEcCtD
Rizatriptan—Anorexia—Doxorubicin—urinary bladder cancer	0.000569	0.000591	CcSEcCtD
Rizatriptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000568	0.00059	CcSEcCtD
Rizatriptan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000568	0.00059	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000563	0.000586	CcSEcCtD
Rizatriptan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000561	0.000582	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000557	0.000579	CcSEcCtD
Rizatriptan—Fatigue—Epirubicin—urinary bladder cancer	0.000556	0.000578	CcSEcCtD
Rizatriptan—Constipation—Epirubicin—urinary bladder cancer	0.000551	0.000573	CcSEcCtD
Rizatriptan—Pain—Epirubicin—urinary bladder cancer	0.000551	0.000573	CcSEcCtD
Rizatriptan—Urticaria—Methotrexate—urinary bladder cancer	0.000547	0.000569	CcSEcCtD
Rizatriptan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000545	0.000566	CcSEcCtD
Rizatriptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000545	0.000566	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000544	0.000565	CcSEcCtD
Rizatriptan—Insomnia—Doxorubicin—urinary bladder cancer	0.00054	0.000561	CcSEcCtD
Rizatriptan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000536	0.000557	CcSEcCtD
Rizatriptan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000532	0.000553	CcSEcCtD
Rizatriptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000531	0.000552	CcSEcCtD
Rizatriptan—Somnolence—Doxorubicin—urinary bladder cancer	0.00053	0.000551	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000527	0.000548	CcSEcCtD
Rizatriptan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000525	0.000546	CcSEcCtD
Rizatriptan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000519	0.000539	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000515	0.000535	CcSEcCtD
Rizatriptan—Fatigue—Doxorubicin—urinary bladder cancer	0.000514	0.000535	CcSEcCtD
Rizatriptan—Urticaria—Epirubicin—urinary bladder cancer	0.000512	0.000532	CcSEcCtD
Rizatriptan—Constipation—Doxorubicin—urinary bladder cancer	0.00051	0.00053	CcSEcCtD
Rizatriptan—Pain—Doxorubicin—urinary bladder cancer	0.00051	0.00053	CcSEcCtD
Rizatriptan—Abdominal pain—Epirubicin—urinary bladder cancer	0.00051	0.00053	CcSEcCtD
Rizatriptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.00051	0.00053	CcSEcCtD
Rizatriptan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000508	0.000528	CcSEcCtD
Rizatriptan—Asthenia—Methotrexate—urinary bladder cancer	0.000494	0.000514	CcSEcCtD
Rizatriptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000492	0.000511	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000488	0.000507	CcSEcCtD
Rizatriptan—Pruritus—Methotrexate—urinary bladder cancer	0.000488	0.000507	CcSEcCtD
Rizatriptan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000475	0.000494	CcSEcCtD
Rizatriptan—Urticaria—Doxorubicin—urinary bladder cancer	0.000474	0.000493	CcSEcCtD
Rizatriptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000472	0.00049	CcSEcCtD
Rizatriptan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000472	0.00049	CcSEcCtD
Rizatriptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000471	0.00049	CcSEcCtD
Rizatriptan—Asthenia—Epirubicin—urinary bladder cancer	0.000463	0.000481	CcSEcCtD
Rizatriptan—Pruritus—Epirubicin—urinary bladder cancer	0.000456	0.000474	CcSEcCtD
Rizatriptan—Dizziness—Methotrexate—urinary bladder cancer	0.000456	0.000473	CcSEcCtD
Rizatriptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000441	0.000458	CcSEcCtD
Rizatriptan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00044	0.000457	CcSEcCtD
Rizatriptan—Vomiting—Methotrexate—urinary bladder cancer	0.000438	0.000455	CcSEcCtD
Rizatriptan—Rash—Methotrexate—urinary bladder cancer	0.000434	0.000451	CcSEcCtD
Rizatriptan—Dermatitis—Methotrexate—urinary bladder cancer	0.000434	0.000451	CcSEcCtD
Rizatriptan—Headache—Methotrexate—urinary bladder cancer	0.000432	0.000449	CcSEcCtD
Rizatriptan—Asthenia—Doxorubicin—urinary bladder cancer	0.000428	0.000445	CcSEcCtD
Rizatriptan—Dizziness—Epirubicin—urinary bladder cancer	0.000426	0.000443	CcSEcCtD
Rizatriptan—Pruritus—Doxorubicin—urinary bladder cancer	0.000422	0.000439	CcSEcCtD
Rizatriptan—Vomiting—Epirubicin—urinary bladder cancer	0.00041	0.000426	CcSEcCtD
Rizatriptan—Nausea—Methotrexate—urinary bladder cancer	0.000409	0.000425	CcSEcCtD
Rizatriptan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000408	0.000424	CcSEcCtD
Rizatriptan—Rash—Epirubicin—urinary bladder cancer	0.000407	0.000422	CcSEcCtD
Rizatriptan—Dermatitis—Epirubicin—urinary bladder cancer	0.000406	0.000422	CcSEcCtD
Rizatriptan—Headache—Epirubicin—urinary bladder cancer	0.000404	0.00042	CcSEcCtD
Rizatriptan—Dizziness—Doxorubicin—urinary bladder cancer	0.000395	0.00041	CcSEcCtD
Rizatriptan—Nausea—Epirubicin—urinary bladder cancer	0.000383	0.000398	CcSEcCtD
Rizatriptan—Vomiting—Doxorubicin—urinary bladder cancer	0.000379	0.000394	CcSEcCtD
Rizatriptan—Rash—Doxorubicin—urinary bladder cancer	0.000376	0.000391	CcSEcCtD
Rizatriptan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000376	0.000391	CcSEcCtD
Rizatriptan—Headache—Doxorubicin—urinary bladder cancer	0.000374	0.000388	CcSEcCtD
Rizatriptan—Nausea—Doxorubicin—urinary bladder cancer	0.000354	0.000368	CcSEcCtD
Rizatriptan—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	3.36e-06	0.00363	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	3.32e-06	0.00358	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	3.13e-06	0.00338	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HDAC4—urinary bladder cancer	3.11e-06	0.00335	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTZ1—urinary bladder cancer	3.04e-06	0.00328	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	2.89e-06	0.00312	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTO2—urinary bladder cancer	2.89e-06	0.00311	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NAT1—urinary bladder cancer	2.89e-06	0.00311	CbGpPWpGaD
Rizatriptan—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	2.88e-06	0.0031	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.76e-06	0.00297	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	2.73e-06	0.00294	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	2.73e-06	0.00294	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	2.7e-06	0.00291	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	2.64e-06	0.00285	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—UGT2B7—urinary bladder cancer	2.64e-06	0.00285	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—GLI1—urinary bladder cancer	2.6e-06	0.00281	CbGpPWpGaD
Rizatriptan—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	2.55e-06	0.00275	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	2.53e-06	0.00273	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	2.38e-06	0.00257	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CYP4B1—urinary bladder cancer	2.38e-06	0.00256	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	2.31e-06	0.0025	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	2.29e-06	0.00247	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	2.27e-06	0.00245	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	2.27e-06	0.00245	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—SLC19A1—urinary bladder cancer	2.24e-06	0.00242	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—CXCL8—urinary bladder cancer	2.22e-06	0.00239	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	2.21e-06	0.00238	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	2.21e-06	0.00238	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PRSS3—urinary bladder cancer	2.19e-06	0.00236	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—CXCL8—urinary bladder cancer	2.17e-06	0.00234	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CXCL8—urinary bladder cancer	2.1e-06	0.00226	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HDAC4—urinary bladder cancer	1.99e-06	0.00214	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	1.98e-06	0.00213	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.97e-06	0.00212	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	1.97e-06	0.00212	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HDAC4—urinary bladder cancer	1.95e-06	0.0021	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	1.93e-06	0.00208	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	1.93e-06	0.00208	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.88e-06	0.00203	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	1.84e-06	0.00199	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	1.84e-06	0.00199	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	1.83e-06	0.00198	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	1.83e-06	0.00197	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.81e-06	0.00195	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—RBX1—urinary bladder cancer	1.79e-06	0.00193	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.76e-06	0.0019	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—TYMP—urinary bladder cancer	1.75e-06	0.00189	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.73e-06	0.00186	CbGpPWpGaD
Rizatriptan—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	1.68e-06	0.00182	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TSC1—urinary bladder cancer	1.68e-06	0.00181	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GLI1—urinary bladder cancer	1.67e-06	0.0018	CbGpPWpGaD
Rizatriptan—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.66e-06	0.00179	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—CXCL8—urinary bladder cancer	1.65e-06	0.00178	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GLI1—urinary bladder cancer	1.63e-06	0.00176	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—JAG1—urinary bladder cancer	1.6e-06	0.00172	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	1.6e-06	0.00172	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NAT2—urinary bladder cancer	1.58e-06	0.00171	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	1.55e-06	0.00167	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HDAC4—urinary bladder cancer	1.48e-06	0.0016	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—RRM2—urinary bladder cancer	1.36e-06	0.00147	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—RHOA—urinary bladder cancer	1.35e-06	0.00146	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CXCL8—urinary bladder cancer	1.34e-06	0.00145	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	1.31e-06	0.00142	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CXCL8—urinary bladder cancer	1.31e-06	0.00142	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	1.3e-06	0.0014	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—S100B—urinary bladder cancer	1.29e-06	0.0014	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—HPGDS—urinary bladder cancer	1.26e-06	0.00136	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ENO2—urinary bladder cancer	1.26e-06	0.00136	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GLI1—urinary bladder cancer	1.24e-06	0.00134	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—RHOA—urinary bladder cancer	1.23e-06	0.00132	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTT1—urinary bladder cancer	1.23e-06	0.00132	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.19e-06	0.00128	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—NCOR1—urinary bladder cancer	1.16e-06	0.00125	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—RBX1—urinary bladder cancer	1.14e-06	0.00123	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—IL2—urinary bladder cancer	1.13e-06	0.00122	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	1.12e-06	0.00121	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—RBX1—urinary bladder cancer	1.12e-06	0.00121	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CXCL8—urinary bladder cancer	1.08e-06	0.00116	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TSC1—urinary bladder cancer	1.07e-06	0.00116	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	1.06e-06	0.00115	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NAT1—urinary bladder cancer	1.06e-06	0.00115	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TSC1—urinary bladder cancer	1.05e-06	0.00113	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.05e-06	0.00113	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—IL2—urinary bladder cancer	1.03e-06	0.00111	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TERT—urinary bladder cancer	1.03e-06	0.00111	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—JAG1—urinary bladder cancer	1.02e-06	0.0011	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NQO1—urinary bladder cancer	1.02e-06	0.0011	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CXCL8—urinary bladder cancer	1e-06	0.00108	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—JAG1—urinary bladder cancer	1e-06	0.00108	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—HRAS—urinary bladder cancer	9.95e-07	0.00107	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	9.73e-07	0.00105	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—FGFR3—urinary bladder cancer	9.41e-07	0.00101	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ESR1—urinary bladder cancer	9.14e-07	0.000986	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	8.76e-07	0.000945	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—RHOA—urinary bladder cancer	8.64e-07	0.000932	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—RBX1—urinary bladder cancer	8.52e-07	0.000919	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTP1—urinary bladder cancer	8.5e-07	0.000916	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	8.46e-07	0.000912	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	8.28e-07	0.000893	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—S100B—urinary bladder cancer	8.27e-07	0.000892	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—S100B—urinary bladder cancer	8.1e-07	0.000874	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	8.06e-07	0.00087	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CREBBP—urinary bladder cancer	8.01e-07	0.000864	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TSC1—urinary bladder cancer	8.01e-07	0.000864	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IGF1—urinary bladder cancer	7.91e-07	0.000853	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—TYMS—urinary bladder cancer	7.9e-07	0.000852	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—EGFR—urinary bladder cancer	7.87e-07	0.000849	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—RHOA—urinary bladder cancer	7.84e-07	0.000846	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NCOR1—urinary bladder cancer	7.81e-07	0.000842	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTM1—urinary bladder cancer	7.81e-07	0.000842	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—RHOA—urinary bladder cancer	7.68e-07	0.000828	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—JAG1—urinary bladder cancer	7.62e-07	0.000822	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.58e-07	0.000818	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GPX1—urinary bladder cancer	7.48e-07	0.000806	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NCOR1—urinary bladder cancer	7.44e-07	0.000803	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—KRAS—urinary bladder cancer	7.44e-07	0.000802	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.43e-07	0.000801	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ERCC2—urinary bladder cancer	7.34e-07	0.000792	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NCOR1—urinary bladder cancer	7.29e-07	0.000786	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—IL2—urinary bladder cancer	7.25e-07	0.000782	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—RHOA—urinary bladder cancer	7.25e-07	0.000782	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—IL2—urinary bladder cancer	7.1e-07	0.000765	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—MTHFR—urinary bladder cancer	6.9e-07	0.000744	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CXCL8—urinary bladder cancer	6.89e-07	0.000743	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	6.74e-07	0.000727	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ERBB2—urinary bladder cancer	6.71e-07	0.000724	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL2—urinary bladder cancer	6.58e-07	0.00071	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TERT—urinary bladder cancer	6.56e-07	0.000707	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.47e-07	0.000697	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TYMP—urinary bladder cancer	6.45e-07	0.000695	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL2—urinary bladder cancer	6.44e-07	0.000695	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	6.44e-07	0.000695	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TERT—urinary bladder cancer	6.42e-07	0.000693	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CXCL8—urinary bladder cancer	6.36e-07	0.000686	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—HRAS—urinary bladder cancer	6.32e-07	0.000682	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.19e-07	0.000668	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—S100B—urinary bladder cancer	6.17e-07	0.000666	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL2—urinary bladder cancer	6.08e-07	0.000656	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—FGFR3—urinary bladder cancer	6.02e-07	0.000649	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCND1—urinary bladder cancer	5.93e-07	0.000639	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	5.89e-07	0.000636	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—RHOA—urinary bladder cancer	5.85e-07	0.000631	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ESR1—urinary bladder cancer	5.84e-07	0.00063	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.83e-07	0.000629	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MMP9—urinary bladder cancer	5.75e-07	0.000621	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CDKN1A—urinary bladder cancer	5.73e-07	0.000618	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	5.72e-07	0.000617	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PTEN—urinary bladder cancer	5.72e-07	0.000617	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.66e-07	0.00061	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PPARG—urinary bladder cancer	5.6e-07	0.000604	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	5.55e-07	0.000599	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EP300—urinary bladder cancer	5.46e-07	0.000588	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	5.41e-07	0.000583	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CREBBP—urinary bladder cancer	5.38e-07	0.00058	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—SRC—urinary bladder cancer	5.3e-07	0.000572	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	5.14e-07	0.000554	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	5.12e-07	0.000552	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	5.06e-07	0.000546	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	5.03e-07	0.000543	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.03e-07	0.000543	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	5.02e-07	0.000541	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	4.95e-07	0.000534	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	4.93e-07	0.000532	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	4.91e-07	0.000529	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	4.89e-07	0.000528	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	4.76e-07	0.000513	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MYC—urinary bladder cancer	4.75e-07	0.000513	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.66e-07	0.000503	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.66e-07	0.000503	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	4.66e-07	0.000502	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EGFR—urinary bladder cancer	4.65e-07	0.000502	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.63e-07	0.0005	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	4.63e-07	0.0005	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	4.54e-07	0.000489	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.52e-07	0.000488	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	4.49e-07	0.000484	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.45e-07	0.00048	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PTGS2—urinary bladder cancer	4.4e-07	0.000475	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—KRAS—urinary bladder cancer	4.39e-07	0.000474	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	4.36e-07	0.00047	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	4.29e-07	0.000463	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	4.2e-07	0.000453	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	4.07e-07	0.000439	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	4.04e-07	0.000436	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.98e-07	0.00043	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.96e-07	0.000427	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TP53—urinary bladder cancer	3.9e-07	0.000421	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	3.89e-07	0.000419	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PTEN—urinary bladder cancer	3.84e-07	0.000414	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	3.82e-07	0.000412	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	3.81e-07	0.000411	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	3.79e-07	0.000409	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	3.77e-07	0.000407	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.76e-07	0.000405	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	3.75e-07	0.000405	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HRAS—urinary bladder cancer	3.73e-07	0.000403	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	3.71e-07	0.0004	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	3.68e-07	0.000397	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	3.67e-07	0.000395	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—EP300—urinary bladder cancer	3.66e-07	0.000395	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	3.66e-07	0.000395	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.65e-07	0.000393	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	3.6e-07	0.000389	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.59e-07	0.000387	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	3.58e-07	0.000386	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	3.55e-07	0.000383	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	3.49e-07	0.000376	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	3.46e-07	0.000373	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	3.42e-07	0.000368	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	3.39e-07	0.000366	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	3.32e-07	0.000358	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	3.2e-07	0.000345	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.18e-07	0.000343	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.13e-07	0.000338	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	3.04e-07	0.000328	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	3.03e-07	0.000327	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.03e-07	0.000327	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	3.01e-07	0.000325	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	2.98e-07	0.000321	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	2.97e-07	0.000321	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.91e-07	0.000314	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	2.91e-07	0.000314	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	2.9e-07	0.000313	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.88e-07	0.000311	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.88e-07	0.000311	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	2.83e-07	0.000305	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	2.81e-07	0.000303	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.76e-07	0.000297	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	2.75e-07	0.000297	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	2.74e-07	0.000296	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.73e-07	0.000295	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	2.73e-07	0.000294	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.71e-07	0.000292	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	2.6e-07	0.000281	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.55e-07	0.000274	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	2.53e-07	0.000273	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	2.5e-07	0.000269	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	2.44e-07	0.000264	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	2.39e-07	0.000258	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	2.34e-07	0.000252	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	2.27e-07	0.000245	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	2.22e-07	0.000239	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	2.1e-07	0.000226	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.06e-07	0.000223	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.98e-07	0.000214	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.86e-07	0.000201	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.78e-07	0.000192	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.62e-07	0.000175	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.42e-07	0.000153	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.35e-07	0.000146	CbGpPWpGaD
